Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
- The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) -
- Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention -
NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds' or the 'Company'), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Company's novel scaffold 5-HT 2C Gq-protein biased agonist, demonstrated a complete elimination of drop attacks in the DBA/2 mouse model.
'DBA/2 is an excellent model for understanding the effect of anti-epileptic drugs (AEDs) on the etiology of seizures,' stated Jan Torleif Pedersen, PhD, MSc, Director, Chief Science Officer, of Bright Minds Biosciences. 'BMB-101 demonstrated dose-dependent efficacy in the DBA/2 mouse model of epilepsy, and drop seizures were completely eliminated. Notably, BMB-101 achieved 100% survival in the DBA/2 model, reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest. SUDEP is the leading cause of seizure-related premature death, particularly in drug-resistant epilepsy patients, and we are extremely pleased to advance our investigative work and build on this preclinical validation.'
The DBA/2 mouse model is an inbred mouse strain in which young DBA/2 mice are susceptible to audiogenic seizures, making them a model for epilepsy studies. This epilepsy model does re-capitulate phenomenon such as tonic/clonic seizures, drop attacks, and sudden unexpected death in epilepsy.
These findings highlight BMB-101's potential to address critical gaps in SUDEP prevention, a leading cause of mortality in Developmental and Epileptic Encephalopathy (DEE) patients. For individuals with Dravet syndrome, the risk of premature death has been estimated as 15-20%, with half or more cases attributed to SUDEP.
About BMB-101
BMB-101 is a novel scaffold 5-HT 2C Gq-protein biased agonist developed using structure-based drug design. It was explicitly designed for chronic treatment of neurological disorders where tolerance and drug resistance are common issues. Biased agonism at the 5-HT 2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target. BMB-101 works exclusively via the Gq-protein signaling pathway and avoids beta-arrestin activation, which is crucial to minimize the risk of receptor desensitization and tolerance development. This provides a novel mechanism, anti-epileptic drug designed to provide sustained seizure relief in hard-to-treat patient populations. In preclinical studies, BMB-101 has demonstrated efficacy in animal models of Dravet Syndrome and numerous models of generalized seizures.
In Phase 1 clinical studies, BMB-101 was given to 64 healthy volunteers in a Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and food-effects study. BMB-101 was demonstrated to be safe and well tolerated at all doses. No Serious Adverse Events (SAEs) were observed, and Adverse Events (AEs) were mild in nature and in line with on-target effects for serotonergic drugs.
An extensive target-engagement study was conducted using both fluid biomarkers (transient prolactin release) and physical biomarkers (Quantitative Electroencephalogram, qEEG). Both methods confirmed robust central target engagement. A qEEG signature typical for anti-epileptic drugs was observed, with a selective depression of EEG power at frequencies observed during epileptic seizures. Furthermore, a potentiation of frontal gamma-power was observed in this study which could indicate the potential for improved cognition.
About Bright Minds
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Forward-Looking Statements
This news release contains 'forward-looking information'. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur, have the potential to occur, or be achieved. Forward-looking statements in this news release include BMB-101 impacting gaps in SUDEP prevention or reducing the risk of death for individuals with Dravet Syndrome, , and future intended use or therapeutic benefit of BMB-101 to treat epilepsy disorders. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These factors include the company's financial position and operational runway, market condition, success of competitors products in respect of epilepsy treatment and timelines related to such products, regulatory risk to operating in the pharmaceutical industry, risk related to BMB-101 failing in development, not receiving required regulatory approvals, or being delayed to a point where it is not commercially viable, risk related to regulatory agencies imposing additional requirements or delay the initiation of clinical trials, or new or changing laws imposing additional requirements; clinical trials may also not demonstrate the safety or efficacy of BMB-101 in the manner needed to allow the product to go into development. It remains uncertain whether BMB-101 can be developed as a safe and effective treatment of Dravet Syndrome or other epilepsy disorders, and if so, whether the product will be commercially accepted and profitable. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Website: www.brightmindsbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
22 minutes ago
- National Post
For Sale: Used U.S.-Canada border crossing going on auction block
The U.S. government is selling a former border crossing facility in Madawaska, Maine, across the Saint John River from Edmunston, N.B. Article content An online auction for the property starts on Wednesday, Aug. 20. The asking price is US$25,000. Article content Bidding for the old Port of Entry (POE) will increase in $1,000 increments, says the U.S. General Services Administration in a press release about the sale. (The GSA is the U.S. government's shared services arm, managing a real estate portfolio of over 360 million rentable square feet.) Article content While the commercial space listing has primarily been used as an office, the real estate ad suggests other potential purposes: manufacturing, warehouse, storage facility, garage/shop. Article content 'GSA is transforming an underutilized border facility into an opportunity for community and economic development,' said Public Buildings Service Regional Commissioner Glenn C. Rotondo in the release. Article content Article content The first floor of the building is 2,900 square feet. There is also a 2,900 square foot finished basement. Article content The southern portion of the property is flat, paved and has a one-storey brick building with two canopies, a guard shack and shed for a generator. Article content The northern half of the property is on a floodplain and can't be built upon. Instead, it consists of a steep, wooded slope leading from a retaining wall down approximately 50 feet to the water line of the Saint John River. The river surrounds the northern edge of the property. A paper mill with a rail line is situated on the other perimeters. Article content Article content The 1959 facility was closed last year when U.S. Customs and Border Protection ceased operations there and relocated to the new Madawaska POE and International Bridge. The new facility will include room for increases in traffic. The new facility, worth roughly $73 million, is also aiming to be include administrative offices and training space. Article content Parts of the old bridge were saved by the town, according to Maine newspaper The County. A local artist pitched a plan to create a 20-foot sculpture of an Acadian star out of materials from the bridge to celebrate the Francophone cultural connection shared by the two countries, across the old bridge created. Article content Acadians are descendants of French settlers who originally settled in Canada's Maritime Provinces in the 17th and 18th centuries. Aroostook County later became a hub of Acadian culture, with a large population still maintaining their heritage.
Globe and Mail
22 minutes ago
- Globe and Mail
Dr. Brian Day predicted the health care mess we're in today
Last month, it was revealed that between 2018 and 2024, almost 142,000 people walked out of an emergency room in British Columbia without being seen by a doctor or a nurse. The numbers make up just some of the data tracked by the province's health ministry. The information was obtained by the BC Conservative Party via a freedom-of-information request because heavens knows these are not the kind of statistics a sitting government wants out there – especially a government that has fought hard to maintain the status quo when it comes to health care in the province. 'It's just really sad that this is what passes for a quality health care system,' Dr. Brian Day says to me over the phone. 'The numbers are shocking, and yet we've seen this coming for years now.' Certainly he has. I've been chronicling Dr. Day's fight against the health care system as we know it for years. And I can say, unequivocally, that he forecast the sorry state of affairs we are living today, with long waits for important surgeries becoming a part of daily life for far too many Canadians. Dr. Day predicted emergency rooms would not have the capacity to meet the growing number of people in Metro Vancouver unless the government went on a major hiring spree. Successive administrations didn't listen, and here we are today. In rural B.C., frequent ER closings show how 'fragile' the health care system has become B.C. health authority cuts dozens of jobs after quiet government directive to balance budget There are few doctors in this country who have been as high-profile and controversial as Dr. Day has been for three decades. He has been the tireless pitchman for a hybrid system of health care that allows for some private providers, like the clinic he's operated in Vancouver for three decades. The journey he's been on has now been chronicled in his new autobiography: My Fight For Canadian Healthcare: A Thirty-Year Battle To Put Patients First. It is a meticulous piece of work with more than 500 references to data and research he says grounds his position in the facts. I would urge all defenders of the great system we have today to spend some time exploring its pages. It's impossible to not come away flummoxed and angry at the gross hypocrisy of those who continue to support a system that perennially underperforms against our peer nations – despite, in many cases, spending far more money. The book walks the reader through Dr. Day's long fight with the B.C. government to allow private health insurance in the province. The struggle, of course, ultimately led to a defeat in B.C. Supreme Court in 2020, with the judge in the case rejecting Dr. Day's argument that British Columbians had a constitutional right to access private care when wait times in the public system put a person's health and life at risk. Ultimately, the Supreme Court of Canada refused to hear an appeal. This would be the same court that in 2005 ruled that private insurance could be allowed in Quebec because, in the words of then-chief justice Beverley McLachlin, 'access to a waiting list is not access to health care.' So private health care is allowed in Quebec, just not anywhere else in Canada. Make that make sense. The ruling against Mr. Day's clinic only applied to B.C. and its residents. So, people in Alberta, for instance, who are tired of waiting for knee or hip surgery there, can come to Dr. Day's clinic and pay to get help. (And they do.) Just as British Columbians tired of being in pain here can go to a private clinic in Alberta and get operated on. (As they do as well.) 'Many Canadians don't realize it, but we're the only country on the planet where most people are prevented from getting private health insurance,' Dr. Day told me. But Ottawa does allow people to have private insurance for things like drug prescriptions. So, again, no private insurance allowed to get diagnosed with a health problem, but it's okay to have it for the drugs needed to remedy your issue. Again, if you can make that make sense, good for you. Dr. Day is 78 years old now and still performing surgeries. He is as animated as ever on the topic of Canadian health care, especially on social media, where he showcases the absolute insanity of the system we live under in his many posts. As he points out in his book, there is nothing like it in the world. 'I think I'm being proven right in terms of the warnings I sounded years ago,' Dr. Day said. 'I do believe that some day people will come to their senses and realize a hybrid model where some private health care is allowed makes sense – which is why all the best health care systems have it.'
CTV News
22 minutes ago
- CTV News
$13M decision in B.C. pre-sale condo case overturned on appeal
A rendering of the PRIMA development in Richmond, B.C., is shown in this image. (Credit: A decision ordering a developer to pay pre-sale condo buyers more than $13 million in damages for breach of contract has been overturned on appeal, with the high court dismissing the case entirely. More than 30 people who made deposits on condos at what was then called the ALFA development in 2015 and 2016 sued Anderson Square Holdings Ltd., alleging breach of contract. The pre-sale purchasers had their contracts terminated by the developer in July of 2019, with the developer citing a legal dispute with contractors and an inability to secure financing. But the units would ultimately be sold – at higher prices – roughly two years later, albeit under the name 'PRIMA,' according to a B.C. Supreme Court decision handed down last year. The buyers' claim was, essentially, that the developer had no right to terminate the contract when it did. The $13,093,900 in damages awarded represented the difference between what the pre-sale buyers paid for their units and what the condos were valued at when the buyers 'repudiated' their contracts by accepting the return of their deposits in August of 2021, according to the 2024 decision. Anderson Square Holdings Ltd. appealed the decision, claiming the lower court judge 'erred' in interpreting crucial clauses in the contract. The developer argued it was 'entitled to terminate the contract' when it became clear construction would not be completed by Sept. 30, 2019, and the three-judge appeal court panel unanimously agreed. Although the appeal court found the clause in question was 'inherently unclear and ambiguous' and 'poorly worded,' the judges determined it gave the developers the right to terminate the agreement without the written consent of the pre-sale buyers in the event the project could not be completed by the specified date, if the circumstances were beyond its 'reasonable control.' The court rejected the pre-sale buyers' argument that the contract remained in effect even without their written consent, saying the result of that interpretation would have 'commercially absurd' results. 'That interpretation would mean that if there were blameless delay, the contract would remain on foot for the duration of the delay, unless the parties agreed otherwise,' the decision said. 'The parties would be automatically locked in for the full extent of the period of blameless delay in construction. Such delay could be indefinite, leaving the purchasers' investments trapped in the project as the vendor works to complete construction.' Finding the lower court judge erred in interpreting the contract, the appeal was allowed and the case dismissed.
